Last $3.90 USD
Change Today -0.06 / -1.52%
Volume 134.8K
ROSG On Other Exchanges
Symbol
Exchange
NASDAQ CM
Berlin
As of 8:10 PM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

rosetta genomics ltd (ROSG) Snapshot

Open
$3.92
Previous Close
$3.96
Day High
$4.05
Day Low
$3.85
52 Week High
03/19/14 - $6.69
52 Week Low
11/20/13 - $2.35
Market Cap
38.3M
Average Volume 10 Days
207.4K
EPS TTM
--
Shares Outstanding
9.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ROSETTA GENOMICS LTD (ROSG)

Related News

No related news articles were found.

rosetta genomics ltd (ROSG) Related Businessweek News

No Related Businessweek News Found

rosetta genomics ltd (ROSG) Details

Rosetta Genomics Ltd. develops and commercializes microRNAs based diagnostic tests and therapeutics. MicroRNAs are a group of genes that are produced using instructions encoded in DNA. It offers diagnostic tests, including Rosetta Cancer Origin test, a microRNA-based diagnostic to identify 42 tumor types that include carcinomas, soft tissue tumors, lymphoma, and other malignancies; Rosetta Mesothelioma test to differentiate mesothelioma, a cancer connected to asbestos exposure and other risk factors, from other carcinomas in the lung and pleura; Rosetta Lung Cancer test, a lung cancer classification test for cytology samples; and Rosetta Kidney Cancer test, a microRNA-based kidney tumor classification test for pathology samples. The company also focuses on developing tissue-based microRNA biomarkers for the differential diagnosis of indeterminate thyroid fine needle aspirate samples; blood-based microRNA biomarkers in order to develop a new diagnostic test for early diagnosis and refined risk stratification of patients following myocardial infarction; microRNA-based diagnostic test for the early diagnosis of Alzheimer’s disease; and blood- or urine-based microRNA biomarkers to develop a diagnostic test for chronic kidney rejection. It distributes its products primarily in Australia, Canada, Greece, India, Israel, New Zealand, Qatar, Romania, Saudi Arabia, Singapore, Turkey, and the United Arab Emirates. The company has a collaboration agreement with Clalit Health Services for the development of a non-invasive microRNA-based assay for the diagnosis of chronic allograft dysfunction or chronic rejection, following kidney transplantation; and a strategic alliance with Marina Biotech, Inc. to develop microRNA-based diagnostics and therapeutics for rare diseases. Rosetta Genomics Ltd. was founded in 2000 and is headquartered in Rehovot, Israel.

45 Employees
Last Reported Date: 03/31/14
Founded in 2000

rosetta genomics ltd (ROSG) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

rosetta genomics ltd (ROSG) Key Developments

Rosetta and Moffitt Enter into Agreement to Develop Thyroid Neoplasia Assay

Rosetta Genomics Ltd. and Moffitt Cancer Center have entered into an agreement for the development and commercialization of Rosetta's thyroid neoplasia assay. Under the agreement, Rosetta will work with Marino Leon, associate member of the Department of Anatomic Pathology at Moffitt. A fine needle aspiration (FNA), a non-surgical procedure used to obtain tissue for analysis by a pathologist, is the standard technique for detecting cancer.

Rosetta Genomics and Marina Biotech Establish Strategic Alliance to Jointly Develop microRNA-Based Diagnostics and Therapeutics for Rare Diseases

Rosetta Genomics Ltd. and Marina Biotech, Inc. jointly announced that they had established a strategic alliance, wherein the companies will collaborate to identify and develop microRNA-based products designed to diagnose and treat various neuromuscular diseases and dystrophies. The Alliance is exclusive as it relates to neuromuscular diseases and dystrophies, with both companies free to develop and collaborate outside this field both during and after the terms of the Alliance. The companies' initial efforts are expected to be focused on Becker and Duchenne muscular dystrophies as well as myotonic dystrophy. Financial terms and other details of the agreement are not being disclosed at this time. Under the terms of the Alliance, Rosetta will apply its industry leading microRNA discovery expertise for the identification of microRNAs involved in the various dystrophy diseases. If the microRNA is determined to be correlative to the disease, Rosetta may further develop the microRNA into a diagnostic for patient identification and stratification. If the microRNA is determined to be involved in the disease pathology and represents a potential therapeutic target, Marina may develop the resulting microRNA-based therapeutic for clinical development.

Rosetta Genomics, Ltd. Announces Consolidated Earnings Results for the Year Ended December 31, 2013; Provides Revenue Guidance for the First Quarter Ended March 31, 2014; Plans to Continue to Invest in the Expansion of its U.S. Commercial Operations

Rosetta Genomics, Ltd. announced consolidated earnings results for the year ended December 31, 2013. For the period, the company reported revenue of USD 405,000 against USD 201,000 a year ago. Operating loss was USD 13,347,000 against USD 8,267,000 a year ago. Loss from continuing operations was USD 13,170,000 against USD 10,696,000 a year ago. Net comprehensive loss after discontinued operations was USD 12,897,000 against USD 10,457,000 a year ago. Basic and diluted net loss per ordinary share from continuing operations was USD 1.37 against USD 2.40 a year ago. Basic and diluted net loss per ordinary share was USD 1.34 against USD 2.35 a year ago. Non-GAAP net loss was USD 12,059,000 or USD 1.26 per basic and diluted share against USD 7,726,000 or USD 1.74 per basic and diluted share a year ago. The company provided revenue guidance for the first quarter ended March 31, 2014. For the period, the company estimated revenue of USD 260,000. The company planned to continue to invest in the expansion of its U.S. commercial operations and will fund further clinical development of its microRNA technology. As a result, the company estimates that net cash requirements to fund operations in 2014 will be in the range of USD 14 million to USD 15 million.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ROSG:US $3.90 USD -0.06

ROSG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Foundation Medicine Inc $24.65 USD -0.10
Genomic Health Inc $26.70 USD +0.54
NeoGenomics Inc $4.21 USD -0.09
Response Genetics Inc $0.88 USD 0.00
Veracyte Inc $14.56 USD -0.36
View Industry Companies
 

Industry Analysis

ROSG

Industry Average

Valuation ROSG Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 96.0x
Price/Book 1.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 40.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ROSETTA GENOMICS LTD, please visit www.rosettagenomics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.